nodes	percent_of_prediction	percent_of_DWPC	metapath
Galantamine—CHRND—pericardium—dilated cardiomyopathy	0.0468	0.511	CbGeAlD
Galantamine—NPN increased—Lisinopril—dilated cardiomyopathy	0.0377	0.0611	CcSEcCtD
Galantamine—Hypersomnia—Lisinopril—dilated cardiomyopathy	0.0181	0.0293	CcSEcCtD
Galantamine—Incontinence—Furosemide—dilated cardiomyopathy	0.018	0.0292	CcSEcCtD
Galantamine—Infarction—Lisinopril—dilated cardiomyopathy	0.017	0.0276	CcSEcCtD
Galantamine—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.0106	0.0172	CcSEcCtD
Galantamine—Leg pain—Lisinopril—dilated cardiomyopathy	0.0102	0.0166	CcSEcCtD
Galantamine—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00936	0.0152	CcSEcCtD
Galantamine—Apathy—Furosemide—dilated cardiomyopathy	0.00881	0.0143	CcSEcCtD
Galantamine—Flat affect—Furosemide—dilated cardiomyopathy	0.00873	0.0142	CcSEcCtD
Galantamine—Lethargy—Spironolactone—dilated cardiomyopathy	0.00857	0.0139	CcSEcCtD
Galantamine—CHRNB2—myocardium—dilated cardiomyopathy	0.00796	0.087	CbGeAlD
Galantamine—Ataxia—Spironolactone—dilated cardiomyopathy	0.0079	0.0128	CcSEcCtD
Galantamine—Nephrolithiasis—Furosemide—dilated cardiomyopathy	0.00783	0.0127	CcSEcCtD
Galantamine—Gastritis—Spironolactone—dilated cardiomyopathy	0.00743	0.0121	CcSEcCtD
Galantamine—CHRND—heart—dilated cardiomyopathy	0.00723	0.0791	CbGeAlD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00687	0.0235	CbGpPWpGaD
Galantamine—Renal failure—Spironolactone—dilated cardiomyopathy	0.00636	0.0103	CcSEcCtD
Galantamine—CHRNB2—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00607	0.0208	CbGpPWpGaD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.006	0.0206	CbGpPWpGaD
Galantamine—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00578	0.00938	CcSEcCtD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00569	0.0195	CbGpPWpGaD
Galantamine—Bladder pain—Furosemide—dilated cardiomyopathy	0.00569	0.00923	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00564	0.0193	CbGpPWpGaD
Galantamine—CHRNB2—heart—dilated cardiomyopathy	0.00556	0.0607	CbGeAlD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00543	0.0186	CbGpPWpGaD
Galantamine—CHRNA9—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00516	0.0177	CbGpPWpGaD
Galantamine—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00511	0.00828	CcSEcCtD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.0051	0.0175	CbGpPWpGaD
Galantamine—CHRNA2—heart—dilated cardiomyopathy	0.00501	0.0548	CbGeAlD
Galantamine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00486	0.00789	CcSEcCtD
Galantamine—Purpura—Furosemide—dilated cardiomyopathy	0.00474	0.00769	CcSEcCtD
Galantamine—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00472	0.00766	CcSEcCtD
Galantamine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00469	0.00761	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—RAC1—dilated cardiomyopathy	0.00468	0.016	CbGpPWpGaD
Galantamine—Lethargy—Furosemide—dilated cardiomyopathy	0.00466	0.00756	CcSEcCtD
Galantamine—CHRNB1—heart—dilated cardiomyopathy	0.00466	0.051	CbGeAlD
Galantamine—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00461	0.00748	CcSEcCtD
Galantamine—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.00459	0.00744	CcSEcCtD
Galantamine—Malaise—Spironolactone—dilated cardiomyopathy	0.00456	0.0074	CcSEcCtD
Galantamine—Cystitis—Lisinopril—dilated cardiomyopathy	0.00456	0.0074	CcSEcCtD
Galantamine—CHRNB3—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00451	0.0155	CbGpPWpGaD
Galantamine—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00446	0.00723	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00444	0.0152	CbGpPWpGaD
Galantamine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00434	0.00705	CcSEcCtD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00431	0.0148	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00428	0.0147	CbGpPWpGaD
Galantamine—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00427	0.00692	CcSEcCtD
Galantamine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00425	0.0069	CcSEcCtD
Galantamine—Dehydration—Furosemide—dilated cardiomyopathy	0.00425	0.00689	CcSEcCtD
Galantamine—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00417	0.00677	CcSEcCtD
Galantamine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00416	0.00675	CcSEcCtD
Galantamine—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00416	0.00674	CcSEcCtD
Galantamine—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00414	0.00671	CcSEcCtD
Galantamine—CHRNA9—Neuronal System—ABCC9—dilated cardiomyopathy	0.00413	0.0141	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00408	0.014	CbGpPWpGaD
Galantamine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00404	0.00655	CcSEcCtD
Galantamine—ACHE—heart—dilated cardiomyopathy	0.00404	0.0442	CbGeAlD
Galantamine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00403	0.00653	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00402	0.0138	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—ACTN2—dilated cardiomyopathy	0.00396	0.0136	CbGpPWpGaD
Galantamine—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00387	0.00627	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00385	0.0132	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00384	0.0131	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.0038	0.013	CbGpPWpGaD
Galantamine—Injury—Lisinopril—dilated cardiomyopathy	0.00373	0.00605	CcSEcCtD
Galantamine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00367	0.00595	CcSEcCtD
Galantamine—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00365	0.00592	CcSEcCtD
Galantamine—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00362	0.00587	CcSEcCtD
Galantamine—CHRNB3—Neuronal System—ABCC9—dilated cardiomyopathy	0.00361	0.0124	CbGpPWpGaD
Galantamine—Renal impairment—Lisinopril—dilated cardiomyopathy	0.0036	0.00584	CcSEcCtD
Galantamine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00356	0.00578	CcSEcCtD
Galantamine—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00356	0.00578	CcSEcCtD
Galantamine—Arthritis—Lisinopril—dilated cardiomyopathy	0.00353	0.00572	CcSEcCtD
Galantamine—CHRNA7—heart—dilated cardiomyopathy	0.00352	0.0385	CbGeAlD
Galantamine—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.0035	0.00567	CcSEcCtD
Galantamine—Renal failure—Furosemide—dilated cardiomyopathy	0.00346	0.00561	CcSEcCtD
Galantamine—CHRNB3—Neuronal System—ACTN2—dilated cardiomyopathy	0.00346	0.0118	CbGpPWpGaD
Galantamine—Pain in extremity—Lisinopril—dilated cardiomyopathy	0.00343	0.00556	CcSEcCtD
Galantamine—CHRNA5—Neuronal System—ABCC9—dilated cardiomyopathy	0.00342	0.0117	CbGpPWpGaD
Galantamine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.0034	0.00552	CcSEcCtD
Galantamine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.0034	0.00552	CcSEcCtD
Galantamine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00333	0.0054	CcSEcCtD
Galantamine—ACHE—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.00333	0.0114	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—ACTN2—dilated cardiomyopathy	0.00328	0.0112	CbGpPWpGaD
Galantamine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00326	0.00529	CcSEcCtD
Galantamine—CHRNG—Neuronal System—ABCC9—dilated cardiomyopathy	0.00326	0.0112	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00324	0.0111	CbGpPWpGaD
Galantamine—Ataxia—Lisinopril—dilated cardiomyopathy	0.00322	0.00523	CcSEcCtD
Galantamine—Dehydration—Lisinopril—dilated cardiomyopathy	0.00319	0.00517	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00316	0.0108	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00314	0.0108	CbGpPWpGaD
Galantamine—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.00313	0.00508	CcSEcCtD
Galantamine—CHRNG—Neuronal System—ACTN2—dilated cardiomyopathy	0.00313	0.0107	CbGpPWpGaD
Galantamine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00312	0.00506	CcSEcCtD
Galantamine—CHRNE—ErbB2/ErbB3 signaling events—RAF1—dilated cardiomyopathy	0.0031	0.0106	CbGpPWpGaD
Galantamine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.0031	0.00502	CcSEcCtD
Galantamine—CHRNE—Neuronal System—ABCC9—dilated cardiomyopathy	0.00307	0.0105	CbGpPWpGaD
Galantamine—Visual impairment—Furosemide—dilated cardiomyopathy	0.00305	0.00494	CcSEcCtD
Galantamine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00304	0.00493	CcSEcCtD
Galantamine—Gastritis—Lisinopril—dilated cardiomyopathy	0.00303	0.00492	CcSEcCtD
Galantamine—BCHE—cardiac ventricle—dilated cardiomyopathy	0.00303	0.0331	CbGeAlD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00302	0.0103	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00299	0.0102	CbGpPWpGaD
Galantamine—BCHE—Glycerophospholipid biosynthesis—TAZ—dilated cardiomyopathy	0.00297	0.0102	CbGpPWpGaD
Galantamine—Eye disorder—Furosemide—dilated cardiomyopathy	0.00295	0.00479	CcSEcCtD
Galantamine—Tinnitus—Furosemide—dilated cardiomyopathy	0.00295	0.00478	CcSEcCtD
Galantamine—CHRNE—Neuronal System—ACTN2—dilated cardiomyopathy	0.00294	0.0101	CbGpPWpGaD
Galantamine—ACHE—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.0029	0.00994	CbGpPWpGaD
Galantamine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00287	0.00465	CcSEcCtD
Galantamine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00286	0.00463	CcSEcCtD
Galantamine—CHRNB2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00285	0.00978	CbGpPWpGaD
Galantamine—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00285	0.00462	CcSEcCtD
Galantamine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00282	0.00458	CcSEcCtD
Galantamine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00282	0.00458	CcSEcCtD
Galantamine—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00275	0.00447	CcSEcCtD
Galantamine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00275	0.00446	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00274	0.0094	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00273	0.00937	CbGpPWpGaD
Galantamine—Dizziness—Spironolactone—dilated cardiomyopathy	0.00273	0.00443	CcSEcCtD
Galantamine—Flatulence—Furosemide—dilated cardiomyopathy	0.00271	0.0044	CcSEcCtD
Galantamine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00269	0.00437	CcSEcCtD
Galantamine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00268	0.00435	CcSEcCtD
Galantamine—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00267	0.00433	CcSEcCtD
Galantamine—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00266	0.00431	CcSEcCtD
Galantamine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00265	0.00429	CcSEcCtD
Galantamine—Depression—Lisinopril—dilated cardiomyopathy	0.00263	0.00427	CcSEcCtD
Galantamine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00262	0.00426	CcSEcCtD
Galantamine—Rash—Spironolactone—dilated cardiomyopathy	0.0026	0.00422	CcSEcCtD
Galantamine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0026	0.00422	CcSEcCtD
Galantamine—Renal failure—Lisinopril—dilated cardiomyopathy	0.0026	0.00421	CcSEcCtD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00259	0.00889	CbGpPWpGaD
Galantamine—Vision blurred—Furosemide—dilated cardiomyopathy	0.00259	0.00421	CcSEcCtD
Galantamine—CHRNA6—Neuronal System—ABCC9—dilated cardiomyopathy	0.00259	0.00888	CbGpPWpGaD
Galantamine—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00259	0.0042	CcSEcCtD
Galantamine—Headache—Spironolactone—dilated cardiomyopathy	0.00259	0.00419	CcSEcCtD
Galantamine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00257	0.00416	CcSEcCtD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00257	0.0088	CbGpPWpGaD
Galantamine—Anaemia—Furosemide—dilated cardiomyopathy	0.00254	0.00412	CcSEcCtD
Galantamine—Agitation—Furosemide—dilated cardiomyopathy	0.00253	0.0041	CcSEcCtD
Galantamine—Haematuria—Lisinopril—dilated cardiomyopathy	0.00252	0.00408	CcSEcCtD
Galantamine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.0025	0.00405	CcSEcCtD
Galantamine—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00249	0.00404	CcSEcCtD
Galantamine—CHRNA6—Neuronal System—ACTN2—dilated cardiomyopathy	0.00248	0.00851	CbGpPWpGaD
Galantamine—Vertigo—Furosemide—dilated cardiomyopathy	0.00247	0.00401	CcSEcCtD
Galantamine—Nausea—Spironolactone—dilated cardiomyopathy	0.00245	0.00398	CcSEcCtD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00244	0.00836	CbGpPWpGaD
Galantamine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00241	0.00392	CcSEcCtD
Galantamine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00238	0.00386	CcSEcCtD
Galantamine—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00237	0.00385	CcSEcCtD
Galantamine—Hallucination—Lisinopril—dilated cardiomyopathy	0.00236	0.00383	CcSEcCtD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—RAC1—dilated cardiomyopathy	0.00235	0.00806	CbGpPWpGaD
Galantamine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00234	0.0038	CcSEcCtD
Galantamine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00234	0.00379	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00233	0.00377	CcSEcCtD
Galantamine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00232	0.00377	CcSEcCtD
Galantamine—ACHE—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.00232	0.00796	CbGpPWpGaD
Galantamine—Dry mouth—Furosemide—dilated cardiomyopathy	0.00229	0.00372	CcSEcCtD
Galantamine—CHRNB2—Neuronal System—ABCC9—dilated cardiomyopathy	0.00228	0.00782	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00227	0.00778	CbGpPWpGaD
Galantamine—Confusional state—Furosemide—dilated cardiomyopathy	0.00226	0.00367	CcSEcCtD
Galantamine—CHRNB4—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00225	0.0077	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00224	0.00767	CbGpPWpGaD
Galantamine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00221	0.00359	CcSEcCtD
Galantamine—Shock—Furosemide—dilated cardiomyopathy	0.00221	0.00358	CcSEcCtD
Galantamine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.0022	0.00357	CcSEcCtD
Galantamine—Flushing—Lisinopril—dilated cardiomyopathy	0.0022	0.00357	CcSEcCtD
Galantamine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.0022	0.00357	CcSEcCtD
Galantamine—CHRNB2—Neuronal System—ACTN2—dilated cardiomyopathy	0.00219	0.00749	CbGpPWpGaD
Galantamine—Skin disorder—Furosemide—dilated cardiomyopathy	0.00218	0.00354	CcSEcCtD
Galantamine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00217	0.00352	CcSEcCtD
Galantamine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00215	0.00349	CcSEcCtD
Galantamine—Anorexia—Furosemide—dilated cardiomyopathy	0.00214	0.00347	CcSEcCtD
Galantamine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00212	0.00344	CcSEcCtD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—ACTN2—dilated cardiomyopathy	0.00212	0.00725	CbGpPWpGaD
Galantamine—Hypotension—Furosemide—dilated cardiomyopathy	0.0021	0.0034	CcSEcCtD
Galantamine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00208	0.00337	CcSEcCtD
Galantamine—BCHE—Phospholipid metabolism—TAZ—dilated cardiomyopathy	0.00207	0.0071	CbGpPWpGaD
Galantamine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00206	0.00335	CcSEcCtD
Galantamine—CHRNA3—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00206	0.00704	CbGpPWpGaD
Galantamine—Flatulence—Lisinopril—dilated cardiomyopathy	0.00203	0.0033	CcSEcCtD
Galantamine—Tension—Lisinopril—dilated cardiomyopathy	0.00203	0.00329	CcSEcCtD
Galantamine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00202	0.00328	CcSEcCtD
Galantamine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00202	0.00327	CcSEcCtD
Galantamine—Nervousness—Lisinopril—dilated cardiomyopathy	0.00201	0.00325	CcSEcCtD
Galantamine—Back pain—Lisinopril—dilated cardiomyopathy	0.002	0.00324	CcSEcCtD
Galantamine—Somnolence—Furosemide—dilated cardiomyopathy	0.002	0.00324	CcSEcCtD
Galantamine—BCHE—heart—dilated cardiomyopathy	0.00199	0.0217	CbGeAlD
Galantamine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00198	0.00322	CcSEcCtD
Galantamine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00195	0.00317	CcSEcCtD
Galantamine—CHRNA7—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00195	0.00668	CbGpPWpGaD
Galantamine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00195	0.00316	CcSEcCtD
Galantamine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00194	0.00314	CcSEcCtD
Galantamine—Fatigue—Furosemide—dilated cardiomyopathy	0.00194	0.00314	CcSEcCtD
Galantamine—Tremor—Lisinopril—dilated cardiomyopathy	0.00193	0.00314	CcSEcCtD
Galantamine—CHRNA1—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00193	0.00661	CbGpPWpGaD
Galantamine—Constipation—Furosemide—dilated cardiomyopathy	0.00192	0.00311	CcSEcCtD
Galantamine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00192	0.00311	CcSEcCtD
Galantamine—Anaemia—Lisinopril—dilated cardiomyopathy	0.00191	0.00309	CcSEcCtD
Galantamine—Malaise—Lisinopril—dilated cardiomyopathy	0.00186	0.00302	CcSEcCtD
Galantamine—Vertigo—Lisinopril—dilated cardiomyopathy	0.00185	0.00301	CcSEcCtD
Galantamine—Syncope—Lisinopril—dilated cardiomyopathy	0.00185	0.003	CcSEcCtD
Galantamine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00185	0.003	CcSEcCtD
Galantamine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00184	0.00298	CcSEcCtD
Galantamine—CHRNA2—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00183	0.00628	CbGpPWpGaD
Galantamine—Palpitations—Lisinopril—dilated cardiomyopathy	0.00182	0.00296	CcSEcCtD
Galantamine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00181	0.00294	CcSEcCtD
Galantamine—CHRND—Neuronal System—ABCC9—dilated cardiomyopathy	0.00181	0.00622	CbGpPWpGaD
Galantamine—Cough—Lisinopril—dilated cardiomyopathy	0.0018	0.00292	CcSEcCtD
Galantamine—CHRNB4—Neuronal System—ABCC9—dilated cardiomyopathy	0.0018	0.00615	CbGpPWpGaD
Galantamine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00178	0.00288	CcSEcCtD
Galantamine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00178	0.00288	CcSEcCtD
Galantamine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00176	0.00285	CcSEcCtD
Galantamine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00176	0.00285	CcSEcCtD
Galantamine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00176	0.00285	CcSEcCtD
Galantamine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00175	0.00284	CcSEcCtD
Galantamine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00175	0.00283	CcSEcCtD
Galantamine—CHRND—Neuronal System—ACTN2—dilated cardiomyopathy	0.00174	0.00596	CbGpPWpGaD
Galantamine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00174	0.00282	CcSEcCtD
Galantamine—CHRNB4—Neuronal System—ACTN2—dilated cardiomyopathy	0.00172	0.0059	CbGpPWpGaD
Galantamine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00172	0.00279	CcSEcCtD
Galantamine—Confusional state—Lisinopril—dilated cardiomyopathy	0.0017	0.00276	CcSEcCtD
Galantamine—BCHE—cardiac atrium—dilated cardiomyopathy	0.0017	0.0186	CbGeAlD
Galantamine—Shock—Lisinopril—dilated cardiomyopathy	0.00166	0.00269	CcSEcCtD
Galantamine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00165	0.00268	CcSEcCtD
Galantamine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00165	0.00268	CcSEcCtD
Galantamine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00164	0.00267	CcSEcCtD
Galantamine—CHRNA3—Neuronal System—ABCC9—dilated cardiomyopathy	0.00164	0.00563	CbGpPWpGaD
Galantamine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00164	0.00265	CcSEcCtD
Galantamine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00163	0.00264	CcSEcCtD
Galantamine—Asthenia—Furosemide—dilated cardiomyopathy	0.00161	0.00261	CcSEcCtD
Galantamine—ACHE—Monoamine Transport—AGT—dilated cardiomyopathy	0.00161	0.00552	CbGpPWpGaD
Galantamine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00161	0.0026	CcSEcCtD
Galantamine—CHRNA4—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00159	0.00545	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—ACTN2—dilated cardiomyopathy	0.00158	0.0054	CbGpPWpGaD
Galantamine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00157	0.00255	CcSEcCtD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00157	0.00537	CbGpPWpGaD
Galantamine—CHRNA9—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00156	0.00535	CbGpPWpGaD
Galantamine—CHRNA1—ErbB2/ErbB3 signaling events—RAF1—dilated cardiomyopathy	0.00156	0.00535	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—ABCC9—dilated cardiomyopathy	0.00156	0.00534	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—ABCC9—dilated cardiomyopathy	0.00154	0.00529	CbGpPWpGaD
Galantamine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00154	0.00249	CcSEcCtD
Galantamine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00154	0.00249	CcSEcCtD
Galantamine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00152	0.00247	CcSEcCtD
Galantamine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00151	0.00245	CcSEcCtD
Galantamine—Somnolence—Lisinopril—dilated cardiomyopathy	0.0015	0.00243	CcSEcCtD
Galantamine—CHRNA7—Neuronal System—ACTN2—dilated cardiomyopathy	0.00149	0.00512	CbGpPWpGaD
Galantamine—Dizziness—Furosemide—dilated cardiomyopathy	0.00149	0.00241	CcSEcCtD
Galantamine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00148	0.00241	CcSEcCtD
Galantamine—CHRNA1—Neuronal System—ACTN2—dilated cardiomyopathy	0.00148	0.00507	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—ABCC9—dilated cardiomyopathy	0.00147	0.00502	CbGpPWpGaD
Galantamine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00146	0.00238	CcSEcCtD
Galantamine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00145	0.00236	CcSEcCtD
Galantamine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00145	0.00236	CcSEcCtD
Galantamine—Constipation—Lisinopril—dilated cardiomyopathy	0.00144	0.00234	CcSEcCtD
Galantamine—Vomiting—Furosemide—dilated cardiomyopathy	0.00143	0.00232	CcSEcCtD
Galantamine—Rash—Furosemide—dilated cardiomyopathy	0.00142	0.0023	CcSEcCtD
Galantamine—Dermatitis—Furosemide—dilated cardiomyopathy	0.00141	0.00229	CcSEcCtD
Galantamine—Headache—Furosemide—dilated cardiomyopathy	0.00141	0.00228	CcSEcCtD
Galantamine—CHRNA2—Neuronal System—ACTN2—dilated cardiomyopathy	0.00141	0.00481	CbGpPWpGaD
Galantamine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00139	0.00225	CcSEcCtD
Galantamine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00138	0.00223	CcSEcCtD
Galantamine—CHRNB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00137	0.00468	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00136	0.00466	CbGpPWpGaD
Galantamine—Nausea—Furosemide—dilated cardiomyopathy	0.00133	0.00216	CcSEcCtD
Galantamine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00133	0.00216	CcSEcCtD
Galantamine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00133	0.00216	CcSEcCtD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00132	0.00452	CbGpPWpGaD
Galantamine—CHRNA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00129	0.00444	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—ABCC9—dilated cardiomyopathy	0.00127	0.00435	CbGpPWpGaD
Galantamine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00124	0.00201	CcSEcCtD
Galantamine—CHRNG—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00124	0.00423	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00123	0.00423	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—ACTN2—dilated cardiomyopathy	0.00122	0.00417	CbGpPWpGaD
Galantamine—Asthenia—Lisinopril—dilated cardiomyopathy	0.00121	0.00196	CcSEcCtD
Galantamine—CYP2D6—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00119	0.00408	CbGpPWpGaD
Galantamine—CHRNA9—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.00117	0.00403	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—ACE—dilated cardiomyopathy	0.00116	0.00399	CbGpPWpGaD
Galantamine—CHRNE—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00116	0.00398	CbGpPWpGaD
Galantamine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00115	0.00187	CcSEcCtD
Galantamine—ACHE—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00113	0.00389	CbGpPWpGaD
Galantamine—Dizziness—Lisinopril—dilated cardiomyopathy	0.00111	0.00181	CcSEcCtD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00107	0.00367	CbGpPWpGaD
Galantamine—Vomiting—Lisinopril—dilated cardiomyopathy	0.00107	0.00174	CcSEcCtD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00107	0.00367	CbGpPWpGaD
Galantamine—Rash—Lisinopril—dilated cardiomyopathy	0.00106	0.00172	CcSEcCtD
Galantamine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00106	0.00172	CcSEcCtD
Galantamine—Headache—Lisinopril—dilated cardiomyopathy	0.00106	0.00171	CcSEcCtD
Galantamine—BCHE—Peptide hormone metabolism—ACE—dilated cardiomyopathy	0.00104	0.00356	CbGpPWpGaD
Galantamine—CHRNB3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.00103	0.00352	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00101	0.00347	CbGpPWpGaD
Galantamine—Nausea—Lisinopril—dilated cardiomyopathy	0.001	0.00162	CcSEcCtD
Galantamine—CHRNB2—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000995	0.00341	CbGpPWpGaD
Galantamine—CHRNA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000981	0.00336	CbGpPWpGaD
Galantamine—CHRNA5—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000973	0.00334	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000929	0.00318	CbGpPWpGaD
Galantamine—CHRNG—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000929	0.00318	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—ABCC9—dilated cardiomyopathy	0.000907	0.00311	CbGpPWpGaD
Galantamine—CHRNA9—Neuronal System—RAF1—dilated cardiomyopathy	0.0009	0.00308	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.000874	0.00299	CbGpPWpGaD
Galantamine—CHRNE—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000873	0.00299	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—ACTN2—dilated cardiomyopathy	0.000869	0.00298	CbGpPWpGaD
Galantamine—CHRNB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000864	0.00296	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—ABCC9—dilated cardiomyopathy	0.000809	0.00277	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000796	0.00273	CbGpPWpGaD
Galantamine—CHRNB3—Neuronal System—RAF1—dilated cardiomyopathy	0.000787	0.0027	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—ACTN2—dilated cardiomyopathy	0.000775	0.00266	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000757	0.00259	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000748	0.00256	CbGpPWpGaD
Galantamine—CHRNA5—Neuronal System—RAF1—dilated cardiomyopathy	0.000746	0.00256	CbGpPWpGaD
Galantamine—CHRNA6—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000738	0.00253	CbGpPWpGaD
Galantamine—ACHE—Peptide hormone metabolism—AGT—dilated cardiomyopathy	0.000737	0.00253	CbGpPWpGaD
Galantamine—ACHE—Monoamine Transport—TNF—dilated cardiomyopathy	0.00073	0.0025	CbGpPWpGaD
Galantamine—CHRNG—Neuronal System—RAF1—dilated cardiomyopathy	0.000712	0.00244	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.00071	0.00243	CbGpPWpGaD
Galantamine—CHRND—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000687	0.00235	CbGpPWpGaD
Galantamine—CHRNB4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00068	0.00233	CbGpPWpGaD
Galantamine—CHRNE—Neuronal System—RAF1—dilated cardiomyopathy	0.000669	0.00229	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000667	0.00229	CbGpPWpGaD
Galantamine—BCHE—Peptide hormone metabolism—AGT—dilated cardiomyopathy	0.000658	0.00225	CbGpPWpGaD
Galantamine—CHRNB2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.00065	0.00223	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.000646	0.00221	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.000646	0.00221	CbGpPWpGaD
Galantamine—CHRNA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000622	0.00213	CbGpPWpGaD
Galantamine—CHRNA7—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.00059	0.00202	CbGpPWpGaD
Galantamine—CHRNA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000584	0.002	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—ZBTB17—dilated cardiomyopathy	0.000577	0.00198	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—TAZ—dilated cardiomyopathy	0.000577	0.00198	CbGpPWpGaD
Galantamine—CHRNA6—Neuronal System—RAF1—dilated cardiomyopathy	0.000565	0.00194	CbGpPWpGaD
Galantamine—CHRNA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000555	0.0019	CbGpPWpGaD
Galantamine—CHRNB2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000517	0.00177	CbGpPWpGaD
Galantamine—CHRND—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000517	0.00177	CbGpPWpGaD
Galantamine—CHRNB4—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000511	0.00175	CbGpPWpGaD
Galantamine—CHRNB2—Neuronal System—RAF1—dilated cardiomyopathy	0.000498	0.00171	CbGpPWpGaD
Galantamine—CHRNA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—RAF1—dilated cardiomyopathy	0.000481	0.00165	CbGpPWpGaD
Galantamine—CHRNA3—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000468	0.0016	CbGpPWpGaD
Galantamine—CHRNA7—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000444	0.00152	CbGpPWpGaD
Galantamine—CHRNA1—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000439	0.0015	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000427	0.00146	CbGpPWpGaD
Galantamine—CHRNA2—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000417	0.00143	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000412	0.00141	CbGpPWpGaD
Galantamine—CHRNB4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000407	0.0014	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000404	0.00138	CbGpPWpGaD
Galantamine—CHRND—Neuronal System—RAF1—dilated cardiomyopathy	0.000396	0.00136	CbGpPWpGaD
Galantamine—CHRNB4—Neuronal System—RAF1—dilated cardiomyopathy	0.000392	0.00134	CbGpPWpGaD
Galantamine—CHRNA4—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000362	0.00124	CbGpPWpGaD
Galantamine—CHRNA3—Neuronal System—RAF1—dilated cardiomyopathy	0.000358	0.00123	CbGpPWpGaD
Galantamine—ACHE—Metabolism—ANKRD1—dilated cardiomyopathy	0.000354	0.00121	CbGpPWpGaD
Galantamine—CHRNA7—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000354	0.00121	CbGpPWpGaD
Galantamine—CHRNA7—Neuronal System—RAF1—dilated cardiomyopathy	0.00034	0.00117	CbGpPWpGaD
Galantamine—CHRNA1—Neuronal System—RAF1—dilated cardiomyopathy	0.000337	0.00115	CbGpPWpGaD
Galantamine—ACHE—Metabolism—TAZ—dilated cardiomyopathy	0.000333	0.00114	CbGpPWpGaD
Galantamine—CHRNA2—Neuronal System—RAF1—dilated cardiomyopathy	0.00032	0.0011	CbGpPWpGaD
Galantamine—BCHE—Metabolism—ANKRD1—dilated cardiomyopathy	0.000316	0.00108	CbGpPWpGaD
Galantamine—ACHE—Metabolism—SDHA—dilated cardiomyopathy	0.000301	0.00103	CbGpPWpGaD
Galantamine—BCHE—Metabolism—TAZ—dilated cardiomyopathy	0.000297	0.00102	CbGpPWpGaD
Galantamine—CHRNA4—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000288	0.000988	CbGpPWpGaD
Galantamine—CHRNA4—Neuronal System—RAF1—dilated cardiomyopathy	0.000277	0.00095	CbGpPWpGaD
Galantamine—BCHE—Metabolism—SDHA—dilated cardiomyopathy	0.000269	0.000921	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000268	0.000918	CbGpPWpGaD
Galantamine—ACHE—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000258	0.000884	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.000254	0.000872	CbGpPWpGaD
Galantamine—BCHE—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.00023	0.000789	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—LMNA—dilated cardiomyopathy	0.000227	0.000778	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—ACE—dilated cardiomyopathy	0.00022	0.000752	CbGpPWpGaD
Galantamine—ACHE—Neuronal System—RAF1—dilated cardiomyopathy	0.000198	0.000678	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—ACE—dilated cardiomyopathy	0.000196	0.000671	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000184	0.00063	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000184	0.000629	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.000179	0.000613	CbGpPWpGaD
Galantamine—BCHE—Neuronal System—RAF1—dilated cardiomyopathy	0.000176	0.000604	CbGpPWpGaD
Galantamine—ACHE—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000175	0.000599	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	0.000164	0.000562	CbGpPWpGaD
Galantamine—ACHE—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000161	0.000552	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	0.00016	0.000547	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000145	0.000498	CbGpPWpGaD
Galantamine—BCHE—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	0.000144	0.000493	CbGpPWpGaD
Galantamine—ACHE—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000139	0.000477	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000137	0.000468	CbGpPWpGaD
Galantamine—BCHE—Metabolism of proteins—AGT—dilated cardiomyopathy	0.000124	0.000426	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000124	0.000423	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	9.5e-05	0.000326	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	8.93e-05	0.000306	CbGpPWpGaD
Galantamine—ACHE—Metabolism—GPX1—dilated cardiomyopathy	8.18e-05	0.00028	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	8.08e-05	0.000277	CbGpPWpGaD
Galantamine—ACHE—Metabolism—CD36—dilated cardiomyopathy	7.97e-05	0.000273	CbGpPWpGaD
Galantamine—BCHE—Metabolism—GPX1—dilated cardiomyopathy	7.3e-05	0.00025	CbGpPWpGaD
Galantamine—ACHE—Metabolism—AGT—dilated cardiomyopathy	7.18e-05	0.000246	CbGpPWpGaD
Galantamine—BCHE—Metabolism—CD36—dilated cardiomyopathy	7.11e-05	0.000244	CbGpPWpGaD
Galantamine—BCHE—Metabolism—AGT—dilated cardiomyopathy	6.4e-05	0.000219	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	3.36e-05	0.000115	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	3.27e-05	0.000112	CbGpPWpGaD
Galantamine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	2.94e-05	0.000101	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.19e-05	7.52e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.14e-05	7.32e-05	CbGpPWpGaD
Galantamine—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	1.92e-05	6.59e-05	CbGpPWpGaD
